more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$70.37 USD

+0.14 (0.20%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $70.37 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

Top 40% (101 out of 250)

Industry: Medical - Dental Supplies

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Rise in COVID-19 Test Demand to Boost Abbott (ABT) Q4 Earnings

by Zacks Equity Research Published on January 21,2022

With the latest surge in COVID infections due to the more contagious Omicron variant, Abbott (ABT) is expected to report sequentially stronger diagnostics results for the fourth quarter.

3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio

by Zacks Equity Research Published on January 20,2022

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.

Edwards Lifesciences (EW) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research Published on January 20,2022

Improvement in TAVR and TMTT businesses is expected to have contributed to Edwards Lifesciences' (EW) fourth-quarter results.

Here's Why You Should Retain Change Healthcare (CHNG) Stock

by Zacks Equity Research Published on January 20,2022

Change Healthcare (CHNG) continues to benefit from a robust payment accuracy business. However, intense competition remains a woe.

Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

by Zacks Equity Research Published on January 20,2022

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

DaVita's (DVA) New Buyout to Enhance Transplant Experience

by Zacks Equity Research Published on January 19,2022

DaVita (DVA) acquires MedSleuth which will help simplify the kidney transplant process and provide patients greater access to transplantation.

Should Value Investors Buy These Medical Stocks?

by Zacks Equity Research Published on January 19,2022

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

What's in Store for Intuitive Surgical's (ISRG) Q4 Earnings?

by Zacks Equity Research Published on January 18,2022

Intuitive Surgical's (ISRG) fourth-quarter results are likely to reflect solid performance at the Instruments & Accessories segment.

Inari Medical (NARI) Posts Solid Preliminary Q4, FY2021 Revenues

by Zacks Equity Research Published on January 18,2022

Inari Medical (NARI) posts solid fourth-quarter and full-year 2021 revenue data, courtesy of resilience shown in the face of the COVID-19 induced challenges.

Intuitive Surgical (ISRG) Posts Robust Preliminary Q4 Results

by Zacks Equity Research Published on January 17,2022

Intuitive Surgical (ISRG) posts solid fourth-quarter and full-year 2021 results driven primarily by da Vinci procedure volume growth.

AMN Healthcare (AMN) Reports Solid Preliminary Q4 Revenues

by Zacks Equity Research Published on January 14,2022

AMN Healthcare's (AMN) solid fourth-quarter results are likely to have been boosted by solid segmental performances.

DexCom (DXCM) Posts Solid Preliminary Q4 and 2021 Revenues

by Zacks Equity Research Published on January 11,2022

DexCom (DXCM) posts solid fourth-quarter and full-year 2021 revenue data on the back of resilience shown in the face of the COVID-19 induced challenges.

Here's Why You Should Retain AmerisourceBergen (ABC) Stock

by Zacks Equity Research Published on January 11,2022

AmerisourceBergen (ABC) continues to gain traction from the robust pharmaceutical segment. However, stiff competition is a woe.

BD (BDX) Product Gets FDA Nod, Patient Outcome to Get a Boost

by Zacks Equity Research Published on January 10,2022

Regulatory clearance for BD's (BDX) Kiestra IdentifA system is expected to lead to better patient management via automated sample processing and MALDI target preparation.

Here's Why You Should Retain Baxter (BAX) Stock For Now

by Zacks Equity Research Published on January 07,2022

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.

Walgreens Boots (WBA) Q1 Earnings Top Estimates, 2022 View Up

by Zacks Equity Research Published on January 06,2022

Walgreens Boots' (WBA) revenues increased year over year in the fiscal first quarter, driven by COVID-19 vaccinations and testing.

HSIC vs. COO: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research Published on January 06,2022

HSIC vs. COO: Which Stock Is the Better Value Option?

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

by Zacks Equity Research Published on December 23,2021

Investors are optimistic about Henry Schein's (HSIC) better-than-expected third-quarter results and robust performances by its operating businesses.

Henry Schein's (HSIC) New Deal Broadens Medical Supplies Arm

by Zacks Equity Research Published on December 14,2021

The OMNIA Partners cooperative contract is expected to expand Henry Schein's (HSIC) offerings in the field of Point-of-Care testing, personal protective equipment and essential medical supplies.